Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients-Reference-Cited by-同舟云学术

Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients

Published:2019-07 Issue:1 Volume:54 Page:35-42
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Chen Guan-Jhou^ORCID,Sun Hsin-Yun,Chang Sui-Yuan,Cheng Aristine,Huang Yu-Shan,Lin Kuan-Yin,Huang Yi-Chia,Su Yi-Ching,Liu Wen-Chun,Hung Chien-Ching

Funder

AbbVie

Bristol-Myers Squibb

Merck

Gilead Sciences

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. EACS guidelines version 9.0,2017

2. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel;Saag;JAMA,2018

3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services (DHHS). https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf[accessed 9 May 2019].

4. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

5. Assessment of second-line antiretroviral regimens for HIV therapy in Africa;Paton;N Engl J Med,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest Ethiopia, 2021;HIV/AIDS - Research and Palliative Care;2024-02

2. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound;Journal of Microbiology, Immunology and Infection;2023-10

3. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa;Pediatric Infectious Disease Journal;2023-02-14

4. Identification of human immunodeficiency virus -1 E protein-targeting lead compounds by pharmacophore based screening;Saudi Medical Journal;2022-12

5. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens;International Journal of Antimicrobial Agents;2022-09